» Articles » PMID: 34108481

Structural Basis for Inhibition of the AAA-ATPase Drg1 by Diazaborine

Overview
Journal Nat Commun
Specialty Biology
Date 2021 Jun 10
PMID 34108481
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The hexameric AAA-ATPase Drg1 is a key factor in eukaryotic ribosome biogenesis and initiates cytoplasmic maturation of the large ribosomal subunit by releasing the shuttling maturation factor Rlp24. Drg1 monomers contain two AAA-domains (D1 and D2) that act in a concerted manner. Rlp24 release is inhibited by the drug diazaborine which blocks ATP hydrolysis in D2. The mode of inhibition was unknown. Here we show the first cryo-EM structure of Drg1 revealing the inhibitory mechanism. Diazaborine forms a covalent bond to the 2'-OH of the nucleotide in D2, explaining its specificity for this site. As a consequence, the D2 domain is locked in a rigid, inactive state, stalling the whole Drg1 hexamer. Resistance mechanisms identified include abolished drug binding and altered positioning of the nucleotide. Our results suggest nucleotide-modifying compounds as potential novel inhibitors for AAA-ATPases.

Citing Articles

The novel ribosome biogenesis inhibitor usnic acid blocks nucleolar pre-60S maturation.

Kofler L, Grundmann L, Gerhalter M, Prattes M, Merl-Pham J, Zisser G Nat Commun. 2024; 15(1):7511.

PMID: 39209816 PMC: 11362459. DOI: 10.1038/s41467-024-51754-3.


K29-linked free polyubiquitin chains affect ribosome biogenesis and direct ribosomal proteins to the intranuclear quality control compartment.

Suresh H, Bonneil E, Albert B, Dominique C, Costanzo M, Pons C Mol Cell. 2024; 84(12):2337-2352.e9.

PMID: 38870935 PMC: 11193623. DOI: 10.1016/j.molcel.2024.05.018.


Ribosome biogenesis and function in development and disease.

Ni C, Buszczak M Development. 2023; 150(5).

PMID: 36897354 PMC: 10108708. DOI: 10.1242/dev.201187.


Computational and mitochondrial functional studies of novel compound heterozygous variants in SPATA5 gene support a causal link with epileptogenic encephalopathy.

Raggio V, Grana M, Winiarski E, Mansilla S, Simoes C, Rodriguez S Hum Genomics. 2023; 17(1):14.

PMID: 36849973 PMC: 9972848. DOI: 10.1186/s40246-023-00463-x.


ATPase family AAA domain-containing protein 2 (ATAD2): From an epigenetic modulator to cancer therapeutic target.

Fu J, Zhang J, Chen X, Liu Z, Yang X, He Z Theranostics. 2023; 13(2):787-809.

PMID: 36632213 PMC: 9830439. DOI: 10.7150/thno.78840.


References
1.
Loibl M, Klein I, Prattes M, Schmidt C, Kappel L, Zisser G . The drug diazaborine blocks ribosome biogenesis by inhibiting the AAA-ATPase Drg1. J Biol Chem. 2013; 289(7):3913-22. PMC: 3924260. DOI: 10.1074/jbc.M113.536110. View

2.
Bodnar N, Rapoport T . Molecular Mechanism of Substrate Processing by the Cdc48 ATPase Complex. Cell. 2017; 169(4):722-735.e9. PMC: 5751438. DOI: 10.1016/j.cell.2017.04.020. View

3.
Puchades C, Sandate C, Lander G . The molecular principles governing the activity and functional diversity of AAA+ proteins. Nat Rev Mol Cell Biol. 2019; 21(1):43-58. PMC: 9402527. DOI: 10.1038/s41580-019-0183-6. View

4.
Bianco G, Goodsell D, Forli S . Selective and Effective: Current Progress in Computational Structure-Based Drug Discovery of Targeted Covalent Inhibitors. Trends Pharmacol Sci. 2020; 41(12):1038-1049. PMC: 7669701. DOI: 10.1016/j.tips.2020.10.005. View

5.
Levy C, Baldock C, Wallace A, Sedelnikova S, Viner R, Clough J . A study of the structure-activity relationship for diazaborine inhibition of Escherichia coli enoyl-ACP reductase. J Mol Biol. 2001; 309(1):171-80. DOI: 10.1006/jmbi.2001.4643. View